Evolution of Active Surveillance of Prostate Cancer: Impact of Magnetic Resonance Imaging, Magnetic Resonance Imaging-Guided Biopsy, and Focal Therapy.

Shannon C Martin¹, Samantha Gonzalez², Lorna Kwan², Merdie Delfin², Anissa V Nguyen², Wayne Brisbane², Ely Felker³, Anthony Sisk⁴, Alan Priester^2,5,6, Shyam Natarajan^2,5,6, Leonard S Marks²

¹David Geffen School of Medicine, Los Angeles, California.

²Department of Urology, David Geffen School of Medicine, Los Angeles, California.

³Department of Radiology, David Geffen School of Medicine, Los Angeles, California.

⁴Department of Pathology, David Geffen School of Medicine, Los Angeles, California.

⁵Department of Bioengineering, David Geffen School of Medicine, Los Angeles, California.

⁶Avenda Health, Inc, Culver City, California.

PubMed PMC DOI PDF

Abstract

PURPOSE: We aimed to determine if, using baseline MRI-guided biopsy (MRGB), durability of active surveillance (AS) could be predetermined, follow-up biopsies avoided, and if by incorporating focal therapy (FT), AS extended. MATERIALS AND METHODS: A cohort of 869 men in the University of California, Los Angeles, protocol study of AS (2010-2022) was analyzed. Inclusion criteria were baseline MRGB s…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.